Cannabinoid Research is the Future and AXIM Biotech® is the One to Watch

shutterstock_122776597
This article is sponsored by General Hemp, the world’s leading investment group supporting growth in the industrial hemp industry. General Hemp was founded by a small group of investors and entrepreneurs with the goal of developing new markets for industrial hemp applications, including healthcare and clean energy.

Of the handful of companies conducting clinical trials on cannabinoids, AXIM® Biotechnologies (OTC: AXIM), which was recently featured in Fox Business, has positioned itself as one to watch. Founded in 2010, innovative biotechnology company AXIM Biotech has set the standard for cannabinoid bioscience through the discovery and commercialization of cannabinoid-based pharmaceuticals and supplements.

With AXIM Biotech’s pioneering patents, its innovative pipeline of products and clinical trials, and proven executive management team, this company has set the stage for significant growth over the coming year.

Important Patent Innovations

This past November, AXIM Biotechnologies was granted a patent that claims the use of all cannabinoids in cannabinoid-containing controlled-release chewing gum products. The patent covers the inclusion of all cannabinoids, including tetrahydrocannabinol (THC), in a chewing gum delivery system.

AXIM Biotech had already held the exclusive rights to the world’s first patented cannabinoid release chewing gum, CanChew® Plus, which claimed gum products as a delivery mechanism for a single cannabinoid – cannabidiol (CBD).

Most recently, AXIM Biotech filed an IP application with the World Intellectual Property Organization on a proprietary method to extract tetrahydrocannabinol acid (THC-A) from cannabis flower using a non-polar solvent, offering an avenue for achieving THC with higher purity than conventional methods.

Exciting Product and Clinical Trial Pipelines

AXIM Biotechnologies plans to use its efficient clinical trial process and extensive product pipeline to develop treatments for conditions with no known effective treatment and a large addressable market. The company secured funding in October for clinical trials to evaluate the safety and efficacy of the delivery systems of its cannabinoid-containing controlled-release chewing gum products.

AXIM’s flagship products include CanChew®, a hemp CBD-based controlled released chewing gum that is currently available and marketed as a dietary supplement, and MedChewTM Rx, a gum containing both CBD and THC gum that is currently being researched to enter into clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. Reuters recently estimated the potential economic impact for MedChew Rx on spasticity and pain associated with MS to be $4.8 billion.

CanChew® is legal to purchase wherever CBD hemp oil products are sold, including all 50 U.S. states, no prescription needed. AXIM recently announced that it would be partnering with Wageningen University of The Netherlands to run clinical trials on two different potencies of another product CanChew Plus, a cannabinoid chewing gum that aims to treat Irritable Bowel Syndrome (IBS), which has a global treatment market estimated to grow to $1.5 billion by 2023.

MedChew Rx, positioned to serve as a viable alternative to GW Pharmaceuticals’ spray that goes under-the-tongue, is on pace to be fully registered by the EMA and FDA by 2019. MedChew Rx is being prepared for clinical trials for the treatment of pain and spasticity associated with multiple sclerosis.

Further ahead for AXIM Biotech is their AX-1602 proprietary ointment that contains the cannabinoid cannabigerol (CBG). The CBG based ointment is currently undergoing clinical trials for the treatment of psoriasis and atopic dermatitis.

The leader in cannabinoid research and development, AXIM Biotech has distinguished itself from other firms with its efficient capital allocation. By partnering with world-class education and research institutes, the company has managed to spend very little on its clinical trials.

Other intellectual property protected cannabinoid-based products in AXIM’s pipeline include:

  • RENECANNTM – a skincare product line containing CBG
  • ORAXIMAXTM – an oral care product line containing CBG
  • SuppocannTM – a suppository cannabinoid-release product for gastrointestinal conditions
  • OphthocannTM and CannblephTM – cannabinoid-based products to reduce intraocular pressure

AXIM Biotechnologies’ Proven Leadership Team

Leading AXIM® Biotechnologies is a highly experienced executive team that possesses a wealth of expertise spanning the medical and biotechnology industries.

Serving as Chief Executive Officer and the Secretary of AXIM Biotechnologies is doctor and business leader Dr. George E. Anastassov. Dr. Anastassov helped develop the world’s first cannabinoid-based chewing gum based delivery method and is one of the AXIM Biotech founders. Having earned both medical and dental doctorates, as well as an executive MBA, Dr. Anastassov possesses both the medical knowhow and business acumen to propel AXIM Biotech to becoming the leading biotech company in the burgeoning cannabinoid market.

As the originator of the patent-pending technology on chewing gum compositions comprising cannabinoids, Dr. Philip A. Van Damme serves as AXIM Biotechnologies’ Chief Scientific/Medical Officer of AXIM Biotechnologies. Dr. Van Damme has a long active history in research and development in biotechnologies and medicine, and possesses medical and dental doctorates and a PhD in Medical Sciences. Prior to joining AXIM Biotech, Dr. Van Damme was one of the founders and CSO of CanChew Biotechnologies LLD.

AXIM Biotechnologies’ Chief Technology Officer, Lekhram Changoer, has over 20 years of experience in sales and marketing, research and development, product development, and pharmaceutical products. Changoer is the originator of several patents, including the patent-pending technology on cannabinoid chewing gum compositions.

Positioned for Future Success

With the shifting political climate around the cannabis industry, the cannabinoid market is facing an unprecedented surge of interest and investment and AXIM Biotechnologies remains one to watch.

As the demand for cannabis-derived medications expands across the globe, and with the chewing gum deliver mechanism already being widely implemented with nicotine products, the patents granted to AXIM could prove to be extremely valuable over the coming years.

AXIM recently published a product pipeline chart that highlights the timelines and stages of pre-clinical and clinical trials for its numerous intellectual property-protected cannabinoid products, and offers anticipated market introduction dates, demonstrating that the company is positioning itself to deliver cutting-edge products to an enthusiastic market.